CRISPR Therapeutics Stock Forecast, Price & News

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics or view top-rated stocks.

How has CRISPR Therapeutics' stock been impacted by COVID-19?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has increased by 44.7% and is now trading at $62.61.
View which stocks have been most impacted by COVID-19.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for CRISPR Therapeutics.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Wednesday, November, 3rd. The company reported ($1.67) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.75) by $0.08. The company earned $0.82 million during the quarter, compared to analysts' expectations of $3.85 million. CRISPR Therapeutics had a net margin of 45.64% and a trailing twelve-month return on equity of 19.19%.
View CRISPR Therapeutics' earnings history.

What price target have analysts set for CRSP?

13 analysts have issued twelve-month price objectives for CRISPR Therapeutics' shares. Their forecasts range from $101.00 to $189.00. On average, they anticipate CRISPR Therapeutics' stock price to reach $152.33 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about CRISPR Therapeutics stock?

Here are some recent quotes from research analysts about CRISPR Therapeutics stock:

• 1. SVB Leerink LLC analysts commented, " (10/19/2021)
• 2. According to Zacks Investment Research, "CRISPR Therapeutics' lead pipeline candidate CTX001, a CRISPR gene-edited therapy, is being developed for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in collaboration with Vertex. If successfully developed, CTX001 can reap huge profits as both diseases have a high unmet medical need. The company’s other pipeline candidates are in early-stage development for various cancer indications. However, in absence of a marketed product, it is solely dependent on Vertex for collaborations revenues, which remains a constant woe. Moreover, its candidates are years away from achieving commercialization. Acute competition is also a worry for CRISPR Therapeutics as some companies are developing gene-edited therapies. Shares of the company have outperformed the industry year to date." (2/1/2021)

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:

• Rodger Novak, Chairman & President
• Samarth Kulkarni, Chief Executive Officer & Director (LinkedIn Profile)
• Lawrence O. Klein, Chief Operating Officer
• Brendan Smith, Senior VP, Chief Financial & Accounting Officer
• Tony W. Ho, Executive VP, Head-Research & Development

Who are some of CRISPR Therapeutics' key competitors?

Some companies that are related to CRISPR Therapeutics include Novozymes A/S (NVZMY), Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Repligen (RGEN), Ginkgo Bioworks (DNA), Neurocrine Biosciences (NBIX), Novavax (NVAX), Exelixis (EXEL), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Abcam (ABCM) and Ablynx (ABLYF).
View all of CRSP's competitors.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Carnegie Capital Asset Management LLC (0.15%), Nordea Investment Management AB (0.12%), Cutler Group LP (0.00%), B & T Capital Management DBA Alpha Capital Management (0.03%), Bouvel Investment Partners LLC (0.02%) and Green Alpha Advisors LLC (0.02%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics.

Which institutional investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, B & T Capital Management DBA Alpha Capital Management, Russell Investments Group Ltd., AE Wealth Management LLC, SevenBridge Financial Group LLC, Carnegie Capital Asset Management LLC, Harbor Investment Advisory LLC, and AdvisorNet Financial Inc. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, Michael John Tomsicek, Rodger Novak, and Samarth Kulkarni.
View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks.

Which institutional investors are buying CRISPR Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Cutler Group LP, Nordea Investment Management AB, Aries Wealth Management, U.S. Capital Wealth Advisors LLC, Foundations Investment Advisors LLC, FNY Investment Advisers LLC, Green Alpha Advisors LLC, and Valeo Financial Advisors LLC.
View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $62.61.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $4.79 billion and generates $720 thousand in revenue each year. The company earns $-348.86 million in net income (profit) each year or $4.76 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].